Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.
Department of Obstetrics and Gynaecology, Queen Mary Hospital, Hong Kong, Hong Kong
Community Regional Medical Center, Fresno, California, United States
Hung Vuong Hospital, Ho Chi Minh City, Vietnam
Centre hospitalier Régional de Thiès, Ahmadou Sakhir Ndiéguène, Thiès, Senegal
National OB-GYN Hospital, Hanoi, Vietnam
Post graduate institute of medical education and research, Chandigarh, UT, India
Talkha Central Hospital, Mansoura, Al-Dakahliya, Egypt
Department of Ostetricia e Ginecologia-Ospedale delle Apuane, Massa, MS, Italy
Spectrum Health Hospital, Grand Rapids, Michigan, United States
Al-Azhar University, Faculty of Medicine for Boys ( Cairo ), Al-Hussein University Hospital, Cairo, Egypt
Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States
Ain shams university maternity hospital, Cairo, Egypt
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.